Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2019

Aug 12, 2019

30751_dirs_2019-08-12_077a09c0-050b-421a-8b11-066f6e9592b8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2019-08-08

Reporting Person: ORiordan Anne (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-08-08 Ordinary Shares A 1920 $0.0 Acquired 4760 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-08-08 Non-Qualified Stock Option (right to buy) $137.12 A 4805 Acquired 2029-08-07 Ordinary Shares (4805) Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020.

F2: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019.